

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.*



**IMPACT Therapeutics, Inc**  
**南京英派藥業股份有限公司**

*(A joint stock company established in the People's Republic of China with limited liability)*  
**(Stock Code: 7630)**

**NOTICE OF THE ANNUAL GENERAL MEETING**

**NOTICE IS HEREBY GIVEN** that the annual general meeting (the “**Annual General Meeting**”) of IMPACT Therapeutics, Inc (the “**Company**”) will be held at 10 a.m. on Thursday, June 25, 2026 at Board Room, 27F, New Bund Times Square, 399 West Haiyang Rd., Pudong District, Shanghai, the PRC to consider and, if thought fit, approve the following resolutions. Unless the context otherwise stated, capitalized terms used in this notice shall have the meanings as those defined in the circular of the Company dated June 3, 2026.

**ORDINARY RESOLUTIONS**

1. To consider and approve the work report of the board of directors of the Company (the “**Board**”) for the year 2025;
2. To consider and approve the accountant’s report for the year ended December 31, 2025;
3. To consider and approve the 2025 profit distribution plan of the Company;
4. To consider and approve the re-appointment of auditor of the Company for the year ending December 31, 2026 and to hold office until the conclusion of next annual general meeting of the Company and to authorise the Board to determine its remuneration;

**SPECIAL RESOLUTIONS**

5. To consider and approve the proposed amendments to the Articles of Association;
6. To consider and, if thought fit, pass the following resolution as special resolution:

**“THAT:**

- (A) To consider and approve the grant of a general mandate to the Board and its authorized persons to decide to separately or concurrently allot, issue and/or deal with (including any sale or transfer of treasury shares, if permitted under the Listing Rules) new Shares not exceeding 20% of the total number of Shares

in issue of the Company (excluding any treasury shares) as at the date of passing the relevant resolution at the AGM. The exercise of the general mandate shall comply with conditions below:

- (i) The Board may make or grant Share sales proposal and agreements which would or might require the exercise of such power after the expiry of the earliest of either:
    - (a) the passing of the relevant resolution at the next annual general meeting of the Company; or
    - (b) the date by which the next annual general meeting of the Company is required to be held by the Articles of Association or any applicable laws of the PRC; or
    - (c) the date on which the authorization set out in this resolution is revoked or varied by a special resolution passed by the Shareholders at a general meeting.
  - (ii) The number of Shares to be allotted, issued and/or dealt with (including any sale or transfer of treasury shares, if permitted under the Listing Rules) shall not exceed 20% of the total number of Shares in issue of the Company (excluding any treasury shares) as at the date of passing the relevant resolution at the AGM.
  - (iii) The Board will exercise the power under such mandate in accordance with the PRC Company Law, other applicable laws and regulations of the PRC and the Listing Rules as amended from time to time and upon the necessary approval from the China Securities Regulatory Commission and other relevant authorities.
- (B) The Board be and is hereby authorized to make such amendments to the Articles of Association of the Company as it thinks fit so as to increase the registered share capital and reflect the new capital structure of the Company upon the allotment, issuance of and dealing with shares as contemplated in the above paragraph (A) of this resolution in accordance with the PRC Company Law, other applicable laws and regulations in the PRC and the Listing Rules; and
- (C) Contingent on the Board resolving to allot, issue and deal with shares (including any sale or transfer of treasury shares) of the Company pursuant to paragraph (A) of this resolution, the Board be and is hereby authorized to approve, execute and do or procure to be approved, executed and done, all such documents, deeds and things as it may consider necessary in connection with the issuance, allotment of and dealing with such shares including, without limitation, determining the size of the issue, the issue price, the use of proceeds

from the issue, the target of the issue and the place and time of the issue, making all necessary applications to the relevant authorities, entering into an underwriting agreement or any other agreements, and making all necessary filings and registrations with the relevant PRC, Hong Kong and other authorities.”

7. To consider and, if thought fit, pass the following resolution as special resolution:

**“THAT:**

- (A) subject to paragraph (b) below, the exercise by the Directors of all the powers of the Company to repurchase H shares of the Company on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) or on any other stock exchange on which the shares of the Company may be listed and recognized for this purpose by the Securities and Futures Commission and the Stock Exchange under the Code on Share Buy-backs and, subject to and in accordance with all applicable laws and the Listing Rules, be and is hereby generally and unconditionally approved, such authority to lapse at the earliest of: (i) the conclusion of the next annual general meeting of the Company following the passing of the relevant special resolution(s) at the AGM; (ii) the date by which the next annual general meeting of the Company is required to be held by the Articles of Association or any applicable laws of the PRC; or (iii) the date on which the authority conferred by the relevant special resolution(s) is revoked or varied by a resolution of the Shareholders at any general meeting of the Company; and
- (B) the H Shares which may be repurchased pursuant to the Repurchase General Mandate shall not exceed 10% of the total issued H Shares of the Company (excluding treasury shares) as at the date of passing of the resolution(s) approving the Repurchase General Mandate.”

By order of the Board  
**IMPACT Therapeutics, Inc**  
南京英派藥業股份有限公司  
**Dr. Sui Xiong CAI**

*Executive Director and Chief Executive Officer*

Hong Kong, June 3, 2026

*Notes:*

1. All resolutions at the Annual General Meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The results of the poll will be published on the websites of the Company at [www.impacttherapeutics.com](http://www.impacttherapeutics.com) and Hong Kong Exchanges and Clearing Limited at [www.hkexnews.hk](http://www.hkexnews.hk) after the Annual General Meeting.

2. Any shareholder entitled to attend and vote at the Annual General Meeting convened by the above notice is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy need not be a shareholder of the Company.
3. In order to be valid, the instrument appointing a proxy together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power of attorney or authority, must be completed and returned to the Company's H share registrar of the Company in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (for holders of H Shares), at least 24 hours before the Annual General Meeting (i.e. before 10 a.m. on Wednesday, June 24, 2026) or any adjourned meeting thereof. Completion and return of the form of proxy will not preclude a shareholder from attending and voting at the Annual General Meeting or any adjourned meeting thereof should he/she so wish.
4. For the purpose of determining the list of shareholders who are entitled to attend the Annual General Meeting, the register of members of the Company will be closed from Monday, June 22, 2026 to Thursday, June 25, 2026, both days inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend and vote at the Annual General Meeting, unregistered holders of the shares shall ensure all properly completed transfer documents accompanied by the relevant share certificates must be lodged with the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Thursday, June 18, 2026 for registration.
5. In case of joint shareholders, the vote of the senior joint shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint shareholder(s) and for this purpose, seniority will be determined by the order in which the names stand in the register of members of the Company in respect of the joint shareholding.
6. Shareholders who attend the meeting in person or by proxy shall bear their own travelling and accommodation expenses.
7. A shareholder or his/her proxy should produce proof of identity when attending the Annual General Meeting.
8. References to date and time in this notice are to Hong Kong dates and time.

*As at the date of this notice, the Board of Directors comprises (i) Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA as executive Directors; (ii) Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU as non-executive Directors; and (iii) Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO as independent non-executive Directors.*